ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Effects of Autologous Adipose-Derived Stromal Cells in Patients With Diffuse Lesions in the Brain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01453777
Recruitment Status : Withdrawn (No participants enrolled)
First Posted : October 18, 2011
Last Update Posted : July 21, 2017
Sponsor:
Collaborator:
Instituto de Medicina Regenerativa, S.A. de C.V.
Information provided by (Responsible Party):
Ageless Regenerative Institute

Brief Summary:

The intent of this clinical study is to answer the questions:

  1. Is the proposed treatment safe
  2. Is treatment effective in improving the disease pathology of patients with diffuse brain lesions and clinical outcomes.

Condition or disease Intervention/treatment Phase
Brain Lesion (General) Procedure: harvesting and implantation of adipose derived stem cells Not Applicable

Detailed Description:
This will be an open-label, non-randomized multi-center patient sponsored study of Adipose-Derived Stromal Cells (ASC) implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Via Catheter Into the Internal Carotid Artery and Intravenously in Patients With Diffuse Lesions in the Brain
Study Start Date : May 2011
Estimated Primary Completion Date : December 2014
Estimated Study Completion Date : June 2015

Intervention Details:
  • Procedure: harvesting and implantation of adipose derived stem cells
    Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.


Primary Outcome Measures :
  1. Improvement in standardized Gross Motor Function Measure evaluation compared to baseline [ Time Frame: 3 months ]
  2. Number of participants with adverse events [ Time Frame: up to 6 months ]
    The safety of adipose-derived stem cell injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study injection and up to the 6-month period following treatment.

  3. Improved cognitive function as measured by the mini mental state exam [ Time Frame: 3 months ]
  4. Improvement in standardized Gross Motor Function Measure evaluation compared to baseline [ Time Frame: 6 months ]
  5. Improved cognitive function as measured by the mini mental state exam compared to baseline [ Time Frame: 6 months ]
  6. Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline [ Time Frame: 3 months ]
  7. Reduced depressive symptoms measured by the Beck Depression Inventory compared to baseline [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. number of brain lesions by MRI compared to baseline [ Time Frame: 3 months ]
  2. Improved quality of life scores compared to baseline [ Time Frame: 3 months ]
  3. Improved quality of life scores compared to baseline [ Time Frame: 6 months ]
  4. number of brain lesions by MRI compared to baseline [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males and Females between Age 18 and 80 years.
  • Patient with current diagnosis of Diffuse Brain Lesions with cognitive and/or functional impairment
  • MRI not showing gross atrophy or any other pathology of brain.
  • Up to date on all age and gender appropriate cancer screening per American Cancer Society

Exclusion Criteria:

  • Contraindication for MRI
  • General medical contraindications for minor surgery or angiography
  • Females who are pregnant or nursing or females of childbearing potential who are unwilling to maintain contraceptive therapy for the duration of the study
  • Life expectancy < 6 months due to concomitant illnesses.
  • Exposure to any investigational drug or procedure within 1 month prior to study entry or enrolled in a concurrent study that may confound results of this study.
  • Active infectious disease. Patients known to have tested positive will have an expert consulted as to patient eligibility based on the patient's infectious status
  • Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
  • Patients on chronic immunosuppressive transplant therapy
  • Systolic blood pressure (supine) ≤90 mmHg;
  • Resting heart rate > 100 bpm;
  • Active clinical infection within one week of enrollment.
  • Known drug or alcohol dependence or any other factors which will interfere with the study conduct or interpretation of the results or who in the opinion of the investigator are not suitable to participate.
  • History of cancer (other than non-melanoma skin cancer or in-situ cervical cancer) in the last five years.
  • Unwilling and/or not able to give written informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01453777


Locations
Mexico
Hospital Angeles
Tijuana, Baja California, Mexico, 22010
Sponsors and Collaborators
Ageless Regenerative Institute
Instituto de Medicina Regenerativa, S.A. de C.V.
Investigators
Principal Investigator: Victor D Morales, MD Instituto de Medicina Regenerativa
Principal Investigator: Clemente Zuñiga, md Instituto de Medicina Regenerativa

Responsible Party: Ageless Regenerative Institute
ClinicalTrials.gov Identifier: NCT01453777     History of Changes
Other Study ID Numbers: ADI-ME-DL-001
First Posted: October 18, 2011    Key Record Dates
Last Update Posted: July 21, 2017
Last Verified: March 2017

Keywords provided by Ageless Regenerative Institute:
diffuse brain lesion